Meet RxStrategies in Philadelphia for 340B Summit
Jonathan Ghenn and Rhodie Smith will be attending and meeting with industry leaders during the 4th Annual Covered Entities 340B Summit hosted by World Congress, May 16 – 17 in Philadelphia, PA. RxStrategies is proud to be a Supporting Sponsor for the Summit. This event brings HRSA grantees and covered entities together to discuss the…
Achieve more with advanced analytics
Did you know? Mixed-use inventory virtualization and replenishment platforms through RxStrategies are secure, user-friendly, highly customizable and work with all wholesalers and EHRs. In fact, RxStrategies’ integration of the Medi-Span drug database minimizes the need for manual NDC and multiplier mapping, while system-logic seamlessly complies with state-level MCO reporting requirements. Real-time drug cost analytics…
Simplify 340B with Dashboard Analytics
Our powerful analytics platform provides users with robust and insightful visibility into their 340B program. With an intuitive, cloud-based platform, an advanced reporting machine, and reliable analytics, RxStrategies’ Dashboard Analytics solution simplifies your entire 340B program. Real-time accumulator views, WAC-spend analyses, robust drill-down capabilities, and custom report creations provide our users access to the exact…
The Future of Policy at NACHC 2019
March 27 – 30, RxStrategies representatives Rhodie Smith and Justin Rolling will attend the 2019 Policy and Issues Forum hosted by the National Association of Community Health Centers (NACHC). As one of the largest conferences on health policy, people from all corners of the administration and operations of health care will attend. The priorities…
340B Insider – December 2018
Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. Visit our website to read more. 340B INDUSTRY NEWS Read below for recent news from 340B Health. THE U.S. HOUSE PASSES BILL TO KEEP DRUG COMPANIES FROM OVERCHARGING MEDICAID The bipartisan bill, from…
Clinical Insights: November 7, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Lorbrena® (lorlatinib) – New Drug Approval – November 2, 2018 – The Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with…
Clinical Insights: October 10, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval TegsediTM (inotersen) – October 5, 2018 – Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc., announced that the U.S. Food and Drug…
Clinical Insights: August 30, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval AltrenoTM (tretinoin) – August 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, announced that the U.S. Food and Drug…
Clinical Insights: August 3, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Mulpleta® (lusutrombopag) – July 31, 2018 – The Food and Drug Administration approved lusutrombopag (Mulpleta, Shionogi Inc.) for thrombocytopenia in adults with chronic liver disease who are…
Clinical Insights: July 19, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval SymtuzaTM (darunavir, cobicistat, emtricitabine and tenofovir alafenamide) – July 17, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced the U.S. Food and Drug Administration…
Clinical Insights: June 21, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval Moxidectin – June 13, 2018 – Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases…
Clinical Insights: June 13, 2018
Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. New Drug Approval FulphilaTM (pegfilgrastim-jmdb) – New Biosimilar Drug Approval – June 4, 2018 – The U.S. Food and Drug Administration approved FulphilaTM (pegfilgrastim-jmdb) as the first biosimilar to Neulasta®(pegfilgrastim) to…